Foundation Medicine Expands Molecular Information Decision Support Offerings with GeneKit™, a Genomic Solutions Portal for Pathologists

Powered by FoundationCORE™, GeneKit Enables Unmatched Interpretation, Analysis and Reporting of Genomic Data into Clinical Practice

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ:FMI) today announced the expansion of its suite of molecular information-based products with GeneKit™, a genomics solutions portal for pathologists. Uniquely differentiated by the power of FoundationCORE™, Foundation Medicine's ever-growing comprehensive cancer genomics knowledgebase of more than 50,000 genomic profiles, GeneKit facilitates the interpretation of genomic data generated by pathologists from targeted next generation sequencing (NGS) and "hot spot" assays. This integration will help pathologists to more effectively support clinical diagnosis and treatment strategies via the rapid interpretation and efficient reporting of genomic information to oncology care teams.

"To ensure that molecular information is used to inform therapeutic decisions and improve patient care, we are offering pathologists a sophisticated clinical interpretation system. GeneKit will allow pathologists to assess a patient's specific tumor alterations against a knowledgebase of curated genomic variants, relevant scientific research, targeted therapy and clinical trial information, enabling the creation of actionable reports in a timely fashion for care teams," said David J. Daly, chief commercial officer of Foundation Medicine. "Today, a large number of institutions use manual interpretation procedures that can be incredibly arduous, technical and time-consuming. GeneKit overcomes these challenges of manual reporting and furnishes pathologists with highly relevant clinical and scientific data for the betterment of patient care."

Since hotspot panels are most widely used in pathology laboratories, GeneKit has been designed to seamlessly integrate into a pathologist's standard workflow. GeneKit differs from other pathology reporting tools because of the following key features:

- Integrates with any NGS assay that interrogates the variant status of up to 50 cancer-related genes that are known to be involved in the development, progression and/or treatment of cancers;
- Relies upon FoundationCORE, Foundation Medicine's knowledgebase of comprehensive genomic cancer information;
- Efficiently and rapidly organizes and reports information on up to 50 genes using data from FoundationCORE, as well the customer's proprietary data;
- Easily integrates with other IT systems;
- Offers a user-friendly interface that gives pathologists customized reporting options; and,
- Provides a reflex option to Foundation Medicine's comprehensive genomic profiling assays, FoundationOne® and FoundationOne® Heme.

GeneKit is a cloud-based software solution and is a component of Foundation Medicine's molecular information-based suite of decision support solutions. GeneKit complements Interactive Cancer Explorer® (ICE 2) with PatientMatch™, the company's innovative physician-facing decision support portal. Together, GeneKit and ICE 2 provide an unparalleled offering of molecular information-based solutions that empower cancer care teams to make informed diagnostic and therapeutic care choices based on the unique genomic drivers of each person's cancer.

About Foundation Medicine

Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, FoundationOne® for solid tumors and FoundationOne® Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).
Cautionary Note Regarding Forward-Looking Statements for Foundation Medicine

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the ability of GeneKit to affect the prognosis, treatment or diagnosis of cancer patients, the ability of molecular information to guide identification, characterization and treatment of cancer, including difficult cancers, the benefits and ability of Foundation Medicine's knowledgebase of scientific and medical research, targeted therapy and clinical trials information to affect clinical practice and patient outcomes, and the expansion of our business with pathologists. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that the company is unable to successfully launch its GeneKit product, the GeneKit product does not perform as expected or is not widely accepted, and the risks described under the caption "Risk Factors" in Foundation Medicine's Quarterly Report on Form 10-Q for the quarter ended March 31, 2015, which is on file with the Securities and Exchange Commission, as well as other risks detailed in Foundation Medicine's subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.


Media Contact:
Pure Communications, Inc.
Dan Budwick, 973-271-6085
dan@purecommunicationsinc.com
or
Investor Contact:
Foundation Medicine, Inc.
Susan Hager, 617-418-2258
ir@foundationmedicine.com
or
Matt Clawson, 949-370-8500
matt@purecommunicationsinc.com

Source: Foundation Medicine, Inc.

News Provided by Acquire Media